FGR (7-22)-X13, FGF-X13
General Information
DCTPep ID DCTPep01936
Peptide Name FGR (7-22)-X13, FGF-X13
Sequence AAVALLPAVLLALLAPMPFSTGKRIMLGE
Sequence Length 29
UniProt ID P08620
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Cancer therapy related peptides
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
OCI-AML3 | Adult acute myeloid leukemia; Acute myeloid leukemia | Not active up to 100 µM | CellTox cytotoxicity assay | 30 min | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HEK293: Not active up to 100 µM; HFF: Not active up to 100 µM
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep01936
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C138H235N33O34S2
Absent amino acids CDHNQWY
Theoretical pI 8.79
Acidic residues 1
Basic residues 2
Polar residues 4
Molecular weight (Average) 2964.7
Molecular weight (Monoisotopic) 2962.71
Common amino acids L
Net charge 1
Instability index (II) 51.56
Aliphatic index 148.28
Grand average of hydropathicity (GRAVY) 1.307
Half Life
4.4 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Should not be visible by UV spectrophotometry.
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 26734838
Title Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Year 2016
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID DBAASPS_12678